Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-A3 PET/CT for ACE2 Expression in Lung Cancer
NCT06194630Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-A3 in lung cancer, sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized Uptake Value at 1 year. Status: unknown.
02
Drugs
68Ga-A3
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06194630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194630.